靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究

doi:10.19401/j.cnki.1007-3639.2020.01.004

中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (1): 32-40.doi: 10.19401/j.cnki.1007-3639.2020.01.004

靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究

董　磊 ¹ ，张仲妍 ²

1. 武汉市红十字会医院肿瘤科，湖北武汉 430000 ；
2. 重庆大学附属肿瘤医院中医肿瘤科，重庆 400030

出版日期:2020-01-30 发布日期:2020-01-17
通信作者: 张仲妍 E-mail: kdfirei@sohu.com

Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism

DONG Lei ¹ , ZHANG Zhongyan ²

1. Department of Oncology, Wuhan Red Cross Hospital, Wuhan 430000, Hubei Province, China; 2. Department of Oncology and Traditional Chinese Medicine, Oncology Department, Chongqing University Affiliated Tumor Hospital, Chongqing 400030, China

Published:2020-01-30 Online:2020-01-17
Contact: ZHANG Zhongyan E-mail: kdfirei@sohu.com

摘要/Abstract

摘要： 背景与目的：miR-1290可以调节干扰素调节因子-2（interferon regulatory factor-2，IRF2）的表达，调节非小细胞肺癌（non-small cell lung cancer，NSCLC）的恶性生物学行为，但其具体作用机制目前尚不清楚，因此，探讨miR-1290靶向IRF2对NSCLC细胞增殖、侵袭的调控作用及相关机制。方法：将体外培养的A549细胞分为miR-1290 mimic组、miR-1290 inhibitor组和NC组；实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）和蛋白质印迹法（Western blot）检测各组细胞miR-1290和IRF2的表达，采用荧光素酶实验进一步验证靶向关系。将体外培养的A549细胞分为NC组（转染空白质粒）、miR-1290组（转染miR-1290）、IRF2组（转染IRF2）和miR-1290+IRF2组（转染miR-1290+IRF2）；细胞计数试剂盒（cell counting kit-8，CCK-8）检测各组细胞的增殖活性；Transwell实验检测各组细胞的侵袭，划痕实验检测细胞迁移，Western blot检测各组细胞血管内皮生长因子（vascular endothelial growth factor，VEGF）、E-钙黏着蛋白（E-cadherin）、基质金属蛋白酶（matrix metalloproteinase，MMP）-2和Ki-67。结果：miR-1290可以靶向负调控IRF2的表达；与NC组相比，miR-1290组miR-1290的表达明显上调（P<0.05），IRF2的表达明显下调（P<0.05），细胞增殖活性、侵袭力和迁移率明显上调（P<0.05），VEGF、MMP-2和Ki-67明显上调（P<0.05），E-cadherin水平明显下调（P<0.05），IRF2组IRF2的表达明显上调（P<0.05），细胞增殖活性、侵袭力和迁移率明显下调（P<0.05），VEGF、MMP-2和Ki-67明显下调（P<0.05），E-cadherin水平明显上调（P<0.05）；与IRF2组相比，miR-1290+IRF2组miR-1290的表达明显上调（P<0.05），IRF2的表达明显下调（P<0.05），细胞增殖活性、侵袭力和迁移率明显上调（P<0.05），VEGF、MMP-2和Ki-67明显上调（P<0.05），E-cadherin水平明显下调（P<0.05）。结论：miR-1290可能通过靶向负调控IRF2的表达，促进NSCLC细胞的增殖和侵袭。

关键词: miR-1290, 干扰素调节因子-2, 非小细胞肺癌

Abstract: Background and purpose: miR-1290 can regulate the expression of interferon regulatory factor-2 (IRF2) and the malignant biological behavior of non-small cell lung cancer (NSCLC), but the specific mechanism of its action is still unclear. Therefore, this study explored the regulatory effect of miR-1290 targeting IRF2 on the proliferation and invasion of NSCLC cells and its related mechanism. Methods: A549 cells cultured in vitro were divided into miR-1290 mimic group, miR-1290 inhibitor group and NC group. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot were performed to detect expression of miR-1290 and IRF2 in each group. Their targeted relationship was further verified by fluorescence assay. A549 cells cultured in vitro were divided into NC group (transfected with mimic), miR-1290 group (transfected with miR-1290), IRF2 group (transfected with IRF2) and miR-1290+IRF2 group (transfected with miR-1290+IRF2). Cell counting kit-8 (CCK-8) was performed to detect cell proliferation activity in each group. Transwell assay was performed to detect cell invasion in each group. The cell migration was detected by scratch test. The levels of vascular endothelial growth factor (VEGF), E-cadherin, matrix metalloproteinase (MMP)-2 and Ki-67 in each group were detected by Western blot. Results: IRF2 expression could be negatively regulated by miR-1290. Compared with NC group, miR-1290 expression was significantly up-regulated in miR-1290 group (P<0.05), while IRF2 expression was significantly down-regulated (P<0.05). Moreover, cell proliferation activity, invasion ability and migration rate were significantly increased (P<0.05), levels of VEGF, MMP-2 and Ki-67 were significantly up-regulated (P<0.05), and expression of E-cadherin was significantly down-regulated (P<0.05) in miR-1290 group. IRF2 expression was significantly up-regulated in IRF2 group (P<0.05), cell proliferation activity, invasion ability and migration rate were significantly decreased (P<0.05), levels of VEGF, MMP-2 and Ki-67 were significantly down-regulated (P<0.05), and protein level of E-cadherin was significantly up-regulated (P<0.05). Compared with IRF2 group, miR-1290 expression was significantly up-regulated in miR-1290+IRF2 group, while expression of IRF2 was significantly down-regulated (P<0.05). In addition, cell proliferation activity, invasion ability and migration rate were significantly increased (P<0.05), levels of VEGF, MMP-2 and Ki-67 were significantly up-regulated (P<0.05), and protein level of E-cadherin was significantly down-regulated (P<0.05). Conclusion: MiR-1290 may promote proliferation and invasion of NSCLC cells by negatively regulating IRF2 expression.

Key words: MiR-1290, Interferon regulatory factor-2, Non-small cell lung cancer

董　磊, 张仲妍 . 靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究[J]. 中国癌症杂志, 2020, 30(1): 32-40.

DONG Lei , ZHANG Zhongyan . Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism[J]. China Oncology, 2020, 30(1): 32-40.

[1]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[2]	李海洲, 张艳炜, 许英杰, 杨　门, 张　磊, 韩京军 . miR-933调控KLF6基因影响非小细胞肺癌的作用研究[J]. 中国癌症杂志, 2021, 31(7): 581-588.
[3]	杨　佳, 刘舒媛, 王莹莹, 李盈甫, 马千里, 李　玙, 王永蓉, 李传印, 谭　芳 . 云南省汉族人群TNF-α基因多态性与非小细胞肺癌发生、发展的相关性[J]. 中国癌症杂志, 2021, 31(7): 616-628.
[4]	义维丽, 赵文成, 黄东宁, 覃　莉, 吴新天, 周　斐, 吴凤英 . PD-1单抗治疗非小细胞肺癌相关不良反应及其与疗效的相关性分析[J]. 中国癌症杂志, 2021, 31(3): 203-211.
[5]	赵媛媛, 周建英, 范　云, 王佳蕾, 黄鼎智, 李峻岭, 史美祺, 刘基巍, 姚　煜, 邬　麟, 姚文秀, 张　力 . BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志, 2021, 31(12): 1145-1152.
[6]	申宇嘉, 傅小龙 . 非小细胞肺癌发生、发展过程中免疫微环境变化及其临床意义[J]. 中国癌症杂志, 2021, 31(11): 1115-1125.
[7]	何　夕, 焦晓栋, 臧远胜. 肿瘤突变负荷在EGFR突变型晚期非小细胞肺癌中的临床研究进展[J]. 中国癌症杂志, 2021, 31(1): 69-75.
[8]	鲁晓腾, 许　青. 基于CT影像特征的非小细胞肺癌复发相关性因素研究[J]. 中国癌症杂志, 2020, 30(8): 636-640.
[9]	张龙富, 姚家美, 蒋冬先, 侯英勇, 张　新 . BIM联合Scribble预测晚期非小细胞肺癌化疗效果[J]. 中国癌症杂志, 2020, 30(11): 865-871.
[10]	方瑜佳, 周　娟, 苏春霞. 非小细胞肺癌肝转移免疫微环境及未来干预策略[J]. 中国癌症杂志, 2020, 30(10): 750-758.
[11]	李　媛. 病理学指导下的非小细胞肺癌个体化免疫治疗[J]. 中国癌症杂志, 2020, 30(10): 770-776.
[12]	杨　光, 张　昆, 王　俊 . Prospero相关同源异形盒蛋白1在非小细胞肺癌中的表达及意义[J]. 中国癌症杂志, 2020, 30(10): 791-797.
[13]	叶柯，郑晓丽，葛红，李雪，王浩. TBRG4在肺腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2019, 29(4): 265-271.
[14]	赵雨笛，谭芳，严志凌，李盈甫，戴书颖，周紫云，张新文，刘舒媛，史荔，姚宇峰. CD44基因多态性与宫颈癌及非小细胞肺癌的相关性[J]. 中国癌症杂志, 2019, 29(4): 277-283.
[15]	李静文，周　严，曹淑慧，王　悦，钟　华. 纳武单抗对晚期非小细胞肺癌的疗效和安全性的单中心分析[J]. 中国癌症杂志, 2019, 29(10): 803-808.

靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究

Regulatory effect of miR-1290 targeting IRF2 on proliferation and invasion of non-small cell lung cancer cells and its related mechanism

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价